NCT01332747已完成2 期
Clinical Study on Hyperlipidemia and Comparative Evaluation of Efficacy of a Compound Unani Formulation (Safoof e Muhazzil) and Compressed Tablet of Safoof e Muhazzil in Its Management
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 128
- 试验地点
- 1
- 主要终点
- Total Cholesterol (TC)
研究概览
简要总结
The purpose of this clinical trial is to study the comparative effect of a classical unani antiobesity drug safoof-e-muhazzil on hyperlipidemia in its classical powder form and in compressed tablet form against a standard control.
详细描述
- The largest proportion of cardiovascular diseases is represented by Coronary artery disease(CAD), cerebral and peripheral vascular diseases. During the past decades efficacious strategies have been developed for prevention of these diseases. These strategies involve general lifestyle changes, which include, healthy diet, optimal weight, physical activity, moderate or no alcohol consumption, and smoking cessation, treatment of high blood pressure, control of diabetes mellitus and in particular, treatment of hyperlipidemia.
- Major clinical trials carried out, have shown a clear benefit of low density lipoprotein-cholesterol(LDL-C) reduction in terms of both CAD events and total mortality. A similar reduction in the relative risk of coronary events has been documented in patients with and without clinically evident CAD and in patients with mild or severe hyperlipidemia.
- Hyperlipidemia can be primary which is gene related causing defects in the synthesis of lipoprotein degradation. The other type of hyperlipidemia is secondary which is subsequent to related metabolic abnormalities.
- Although several Unani physicians have mentioned considerable details about fats in blood but it is observed that Hyperlipidemia has not been mentioned per se in the classical Unani literature.
- A condition that resembles hyperlipidemia in various aspects like etiology, clinical features and complications has been described as obesity in the classical Unani literature and mentions related methods for managing such disorders including regimens and drugs (for reducing weight) are also observed in such references.
- Unani physicians have bracketed obesity under cold derangement of temperament.
- Unani physicians have emphasized the effect of Safoof-e-Muhazzil as the main weight loss drug.
- Furthermore, Many of the drugs present in Safoof-e-Muhazzil including Lac which itself is a constituent of Safoof-e-Muhazzil have been attributed by Unani physicians to have de obstruent, desiccant, and softening and relaxant effect on vessel walls properties which further supports our hypothesis. These properties are also in cohesion with our hypothesis and perhaps these drugs may have scraping effect on atherosclerotic vessel walls.
- Lipids are metabolized mainly in the liver and it is the error of the liver or the weakness of the liver that these lipids go unchecked into the blood stream.
- Since most of constituents of Safoof-e-Muhazzil including Lac have been attributed to be liver strengthening agents, hence, due to their corrective effect on liver may help correcting raised lipid levels in the blood.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age 20 Year(s) To 70 Year(s)
- •Gender Both
- •participate in Clinical Trial voluntarily.
- •Hyperlipidemic
排除标准
- •Persons below 20 yrs and Above 70 yrs of age
- •Pregnancy
- •Liver diseases
- •Renal diseases
- •Diabetes mellitus Type II
- •Alcoholic
- •Thyroid Disease
- •Drug intake ? Corticosteroids, Diuretics, Beta-blockers, Oral contraceptives, Cyclosporin, Androgens & Retinoids
研究组 & 干预措施
Safoof e Muhazzil in its conventional powder form
Experimental
safoof e muhazzil in its conventional powder form 5 gms twice daily given orally
干预措施: safoof e muhazzil (Drug)
compressed tablet of safoof e muhazzil
Experimental
compressed tablet of safoof e muhazzil is given in equivalent dose orally
干预措施: compressed tablet of safoof e muhazzil (Drug)
atorvastatin
Active Comparator
atorvastatin 10mg daily as a standard control
干预措施: Atorvastatin (Drug)
结局指标
主要结局
Total Cholesterol (TC)
时间窗: six weeks
High Density Lipoprotein (HDL)
时间窗: six weeks
Low density Lipoprotein (LDL)
时间窗: six weeks
Triglycerides (TG)
时间窗: six weeks
Very Low Density Lipoprotein (VLDL)
时间窗: six weeks
次要结局
- Body Mass Index(six weeks)
- Waist to Hip ratio(six weeks)
研究者
Umar Jahangir
Lecturer
Jamia Hamdard University
研究点 (1)
Loading locations...
相似试验
已完成
2 期
clinical trial to study the comparative effect of a classical unani antiobesity drug safoof-e-muhazzil on hyperlipidemia in its classical powder form and in compressed tablet formCTRI/2011/06/001825Department of Moalejat Medicine Faculty of Medicine90
招募中
不适用
Evaluation of cholesterol lowering efficacy of Rice bran oil, Olive oil and Groundnut oilCTRI/2013/02/003365AP ORGANICS PVT LTD120
已完成
2 期
Treatment of Hyperlipedemia with Unani formulatioCTRI/2018/05/013864Central Council for Research in Unani Medicine60
已完成
4 期
Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELLStrokeDiabetesAtherosclerosisCoronary Heart DiseaseDyslipidemiaNCT00079638Kos Pharmaceuticals300
已完成
不适用
Investigation for the effect of anti-dyslipidemic drugs on serum level of trans-fatty acidsdyslipidemiaJPRN-UMIN000026984Kobe University Graduate School of Medicine40